# Page snapshot

```yaml
- generic [ref=e3]:
  - banner [ref=e4]:
    - generic [ref=e5]:
      - img "OpenOnco" [ref=e7] [cursor=pointer]
      - navigation [ref=e8]:
        - button "Home" [ref=e9] [cursor=pointer]
        - button "Submissions" [ref=e10] [cursor=pointer]
        - button "How it Works" [ref=e11] [cursor=pointer]
        - button "Data Download" [ref=e12] [cursor=pointer]
        - button "FAQ" [ref=e13] [cursor=pointer]
        - button "Learn" [ref=e14] [cursor=pointer]
        - button "About" [ref=e15] [cursor=pointer]
  - main [ref=e16]:
    - generic [ref=e17]:
      - heading "Submissions" [level=1] [ref=e18]
      - paragraph [ref=e19]: Help us improve OpenOnco with your feedback and data contributions.
      - generic [ref=e20]:
        - generic [ref=e21]:
          - generic [ref=e22]: Test Data Update
          - generic [ref=e23]:
            - button "Suggest a New Test Notify us of a test not in our database" [ref=e24] [cursor=pointer]:
              - generic [ref=e25]: Suggest a New Test
              - generic [ref=e26]: Notify us of a test not in our database
            - button "File a Correction Update existing test data" [ref=e27] [cursor=pointer]:
              - generic [ref=e28]: File a Correction
              - generic [ref=e29]: Update existing test data
          - generic [ref=e30]: Bug Reports & Feature Requests
          - generic [ref=e31]:
            - button "Report a Bug Something isn't working correctly" [ref=e32] [cursor=pointer]:
              - generic [ref=e33]: Report a Bug
              - generic [ref=e34]: Something isn't working correctly
            - button "Request a Feature Suggest an improvement or new capability" [ref=e35] [cursor=pointer]:
              - generic [ref=e36]: Request a Feature
              - generic [ref=e37]: Suggest an improvement or new capability
        - button "Vendor Test Validation VENDOR VERIFIED Verify and update your company's test data to earn the VENDOR VERIFIED badge" [ref=e39] [cursor=pointer]:
          - generic [ref=e40]:
            - img [ref=e42]
            - generic [ref=e44]:
              - generic [ref=e45]:
                - generic [ref=e46]: Vendor Test Validation
                - generic [ref=e47]: VENDOR VERIFIED
              - generic [ref=e48]: Verify and update your company's test data to earn the VENDOR VERIFIED badge
            - img [ref=e49]
      - generic [ref=e51]:
        - heading "Database Changelog" [level=2] [ref=e52]
        - paragraph [ref=e53]: Recent updates to the OpenOnco test database, including community contributions.
        - generic [ref=e55]:
          - generic [ref=e56]:
            - generic [ref=e58]: "#58"
            - generic [ref=e59]: +
            - generic [ref=e60]:
              - generic [ref=e61]:
                - generic [ref=e62]: LiquidHALLMARK
                - generic [ref=e63]: TDS
                - generic [ref=e64]: Lucence
              - paragraph [ref=e65]: Added ultrasensitive liquid biopsy combining ctDNA (80 genes) and ctRNA (10 fusion targets). AmpliMark amplicon-based NGS with molecular barcode error correction. Combined ctDNA+ctRNA increases actionable fusion detection by 36.7% vs ctDNA alone. 0.1% VAF LOD for SNVs/indels, 10 copies LOD for RNA fusions. LIQUIK prospective study (JCO Precis Oncol 2025) showed 15.6% more tissue-confirmed NCCN biomarkers detected vs FDA-approved ctDNA-only test. Medicare covered via MolDX (Oct 2024). Available via Mayo Clinic Labs since March 2025. First Asian company to secure Medicare coverage for liquid biopsy in US.
              - generic [ref=e66]:
                - generic [ref=e67]: Dec 19, 2025
                - generic [ref=e68]: "• Vendor update: Jeremy Au (Lucence (vendor))"
          - generic [ref=e69]:
            - generic [ref=e71]: "#57"
            - generic [ref=e72]: +
            - generic [ref=e73]:
              - generic [ref=e74]:
                - generic [ref=e75]: Hedera Profiling 2 ctDNA Test Panel
                - generic [ref=e76]: TDS
                - generic [ref=e77]: Hedera Dx
              - paragraph [ref=e78]: Added decentralized liquid biopsy IVD kit for in-house hospital testing. 32-gene hybrid capture NGS panel covering >80% of ESCAT Level I genes (ESR1, METex14, MSI). DNA-only workflow detects SNVs, indels, CNVs, fusions, MSI at 0.5% VAF LOD. 97% sensitivity, 99.7% specificity in international multicenter validation (10+ centers, 8 countries, 137 clinical samples). Paired with Hedera Prime CE-IVD software for OncoKB-powered therapy matching. CE-IVD (EU/International); requires local validation under CE-IVDR; not available in US.
              - generic [ref=e79]:
                - generic [ref=e80]: Dec 18, 2025
                - generic [ref=e81]: "• Vendor update: Thomas Vetterli (Hedera Dx (vendor))"
          - generic [ref=e82]:
            - generic [ref=e84]: "#56"
            - generic [ref=e85]: +
            - generic [ref=e86]:
              - generic [ref=e87]:
                - generic [ref=e88]: Liquid Trace Solid Tumor
                - generic [ref=e89]: TDS
                - generic [ref=e90]: Genomic Testing Cooperative (GTC)
              - paragraph [ref=e91]: "Added unique cfDNA + cfRNA combined liquid biopsy for solid tumors. Only commercially available liquid biopsy combining both analytes. >1,600 genes via cfRNA. cfRNA enables: higher sensitivity (multiple RNA copies vs single DNA copy), fusion gene detection from chromosomal translocations, expression-level data. LEADING PROVIDER FOR CSF LIQUID BIOPSY - optimal for CNS tumors (glioblastoma, CNS lymphomas/leukemias) and leptomeningeal disease. Includes T/B-cell clonality, HLA genotyping, viral detection (EBV, HPV, TTV). Reports include VAF + mutant molecules/mL for therapeutic monitoring. Medicare covered. NYSDOH approved. CE-marked (EU), UKCA certified (UK)."
              - generic [ref=e92]:
                - generic [ref=e93]: Dec 17, 2025
                - generic [ref=e94]: "• Vendor update: Jeffrey Owen (Genomic Testing Cooperative (vendor))"
          - generic [ref=e95]:
            - generic [ref=e97]: "#55"
            - generic [ref=e98]: +
            - generic [ref=e99]:
              - generic [ref=e100]:
                - generic [ref=e101]: Liquid Trace Hematology
                - generic [ref=e102]: TDS
                - generic [ref=e103]: Genomic Testing Cooperative (GTC)
              - paragraph [ref=e104]: "Added unique cfDNA + cfRNA liquid biopsy for hematologic malignancies. Can significantly reduce need for bone marrow biopsies. Key differentiators: (1) cfDNA chimerism analysis for post-transplant relapse prediction; (2) MRD via mutations AND chromosomal abnormalities (beyond Signatera-style mutation-only approach); (3) T/B-cell clonality; (4) TTV viral load as immune competence marker; (5) CAR-T detection/monitoring in CSF. Published validation: cfDNA detected MORE mutations than bone marrow (92 vs 61); cfDNA chimerism predicted relapse better than CD3+ chimerism (Rowley et al. Cancers 2025). Medicare covered. NYSDOH approved. CE-marked (EU), UKCA certified (UK)."
              - generic [ref=e105]:
                - generic [ref=e106]: Dec 17, 2025
                - generic [ref=e107]: "• Vendor update: Jeffrey Owen (Genomic Testing Cooperative (vendor))"
          - generic [ref=e108]:
            - generic [ref=e110]: "#54"
            - generic [ref=e111]: +
            - generic [ref=e112]:
              - generic [ref=e113]:
                - generic [ref=e114]: Liquid Trace (Therapy Monitoring)
                - generic [ref=e115]: TRM
                - generic [ref=e116]: Genomic Testing Cooperative (GTC)
              - paragraph [ref=e117]: "Added therapy response monitoring entry for Liquid Trace. Only TRM test combining cfDNA + cfRNA. Reports include longitudinal VAF AND mutant molecules/mL tracking table for quantitative response assessment. Response definition: VAF/molecules decrease = response; increase = progression or emerging resistance. Covers both solid tumors and hematologic malignancies. CSF option for CNS involvement and leptomeningeal disease monitoring. For hematology: includes chimerism analysis and chromosomal abnormalities for post-transplant MRD. Medicare covered. NYSDOH approved. CE-marked (EU), UKCA certified (UK)."
              - generic [ref=e118]:
                - generic [ref=e119]: Dec 17, 2025
                - generic [ref=e120]: "• Vendor update: Jeffrey Owen (Genomic Testing Cooperative (vendor))"
          - generic [ref=e121]:
            - generic [ref=e123]: "#53"
            - generic [ref=e124]: +
            - generic [ref=e125]:
              - generic [ref=e126]:
                - generic [ref=e127]: Oncotype DX Breast Recurrence Score
                - generic [ref=e128]: TDS
                - generic [ref=e129]: Exact Sciences
              - paragraph [ref=e130]: Added foundational 21-gene RT-PCR breast cancer assay (in clinical use since 2004). Gene expression profiling for HR+/HER2- early-stage breast cancer. NCCN-preferred with Category 1 evidence. Only test with Level 1 evidence from prospective randomized trials (TAILORx n=10,273; RxPONDER n=5,083) for both prognosis AND chemotherapy benefit prediction. Over 1 million patients tested worldwide. 500+ publications. Medicare covered (~$3,416). First multigene assay to transform breast cancer treatment decisions.
              - generic [ref=e131]:
                - generic [ref=e132]: Dec 17, 2025
                - generic [ref=e133]: • Dr. Don Johann (UAMS (independent expert))
          - generic [ref=e134]:
            - generic [ref=e136]: "#52"
            - generic [ref=e137]: +
            - generic [ref=e138]:
              - generic [ref=e139]:
                - generic [ref=e140]: Avantect Pancreatic Cancer Test
                - generic [ref=e141]: ECD
                - generic [ref=e142]: ClearNote Health
              - paragraph [ref=e143]: "Added first single-cancer ECD test for pancreatic cancer. Uses novel 5-hydroxymethylcytosine (5hmC) cfDNA profiling rather than standard 5mC methylation. 68.3% early-stage (I/II) sensitivity, 96.9% specificity. Targets high-risk population: adults 50+ with new-onset T2DM (within 36 months), genetic predisposition, or family history. Validated in blinded cohort (n=3,674) published in Clin Gastroenterol Hepatol 2023 and J Mol Diagn 2024. Medicare covered at $1,160 (CPT 0410U). NYSDOH approved. Selected for NCI Vanguard study. PRECEDE Consortium member."
              - generic [ref=e144]:
                - generic [ref=e145]: Dec 16, 2025
                - generic [ref=e146]: "• Vendor update: Adrian Vilalta (ClearNote Health (vendor))"
          - generic [ref=e147]:
            - generic [ref=e149]: "#51"
            - generic [ref=e150]: +
            - generic [ref=e151]:
              - generic [ref=e152]:
                - generic [ref=e153]: IUrisure
                - generic [ref=e154]: ECD
                - generic [ref=e155]: Wuhan Ammunition Life Technology
              - paragraph [ref=e156]: Added NMPA-approved urine DNA methylation test for urothelial carcinoma (bladder, ureter, renal pelvis) screening. Dual-target AL021918.2+VIM MSP assay. 93.94% UC sensitivity, 94.44% Ta stage sensitivity, 92.02% specificity. First urine-based methylation test in database. Requires only 1.8 mL urine. Validated at Peking University First Hospital / National Urological Cancer Center (n=477), published in Chinese Med J 2024. Non-invasive alternative to cystoscopy. Available in China only.
              - generic [ref=e157]:
                - generic [ref=e158]: Dec 16, 2025
                - generic [ref=e159]: "• Vendor update: Tingting Li (Wuhan Ammunition Life Technology (vendor))"
          - generic [ref=e160]:
            - generic [ref=e162]: "#50"
            - generic [ref=e163]: +
            - generic [ref=e164]:
              - generic [ref=e165]:
                - generic [ref=e166]: IHepcomf
                - generic [ref=e167]: ECD
                - generic [ref=e168]: Wuhan Ammunition Life Technology
              - paragraph [ref=e169]: Added NMPA/CE-approved plasma cfDNA methylation test for primary liver cancer (PLC) screening. Dual-target GNB4+Riplet qMSP assay. 92.3% PLC sensitivity (91.9% HCC, 93.3% ICC), 84.4% Stage I sensitivity, 93.4% specificity. First plasma methylation test for liver cancer in database. Validated in multicenter, double-blind trial (n=1,182) across 3 Chinese hospitals, published in Clin Epigenetics 2025. Detects HCC, ICC, and combined subtypes. Superior to AFP for early detection. Available in China and Europe.
              - generic [ref=e170]:
                - generic [ref=e171]: Dec 16, 2025
                - generic [ref=e172]: "• Vendor update: Tingting Li (Wuhan Ammunition Life Technology (vendor))"
          - generic [ref=e173]:
            - generic [ref=e175]: "#49"
            - generic [ref=e176]: +
            - generic [ref=e177]:
              - generic [ref=e178]:
                - generic [ref=e179]: IEsohunter
                - generic [ref=e180]: ECD
                - generic [ref=e181]: Wuhan Ammunition Life Technology
              - paragraph [ref=e182]: Added NMPA/CE-approved plasma cfDNA methylation test for esophageal cancer screening. Dual-target OTOP2+KCNA3 qPCR assay. 87.4% EC sensitivity, 78.5% Stage I sensitivity, 93.3% specificity. First commercially available plasma methylation test for esophageal cancer. Validated in prospective, double-blinded, multicenter trial (n=1,116) across 5 Chinese centers, published in J Hematol Oncol 2024. Detects both ESCC and EAC. Available in China and Europe.
              - generic [ref=e183]:
                - generic [ref=e184]: Dec 16, 2025
                - generic [ref=e185]: "• Vendor update: Tingting Li (Wuhan Ammunition Life Technology (vendor))"
          - generic [ref=e186]:
            - generic [ref=e188]: "#48"
            - generic [ref=e189]: +
            - generic [ref=e190]:
              - generic [ref=e191]:
                - generic [ref=e192]: IColohunter
                - generic [ref=e193]: ECD
                - generic [ref=e194]: Wuhan Ammunition Life Technology
              - paragraph [ref=e195]: Added NMPA/CE-approved plasma cfDNA methylation test for CRC screening. Dual-target NTMT1+MAP3K14-AS1 qPCR assay using novel SADMP technique. 91.2% CRC sensitivity, 87.4% Stage I-II sensitivity, 43.5% advanced adenoma sensitivity, 92.4% specificity. Validated in multicenter, double-blinded trial (n=1,194) across 5 Chinese hospitals, published in BMC Medicine 2024. Blood-based complement to vendor's stool-based IColocomf test. Available in China and Europe.
              - generic [ref=e196]:
                - generic [ref=e197]: Dec 16, 2025
                - generic [ref=e198]: "• Vendor update: Tingting Li (Wuhan Ammunition Life Technology (vendor))"
          - generic [ref=e199]:
            - generic [ref=e201]: "#47"
            - generic [ref=e202]: ↑
            - generic [ref=e203]:
              - generic [ref=e204]:
                - generic [ref=e205]: TSO 500
                - generic [ref=e206]: TDS
                - generic [ref=e207]: Illumina
              - paragraph [ref=e208]: "Corrected regulatory status: TSO 500 is RUO (Research Use Only) globally, not CE-IVD in EU. The CE-IVD marking belongs to TruSight Oncology Comprehensive (TSO Comp), which is a separate IVD product. Updated fdaStatus, productType, indicationsNotes, clinicalAvailability, and technologyDifferentiator fields."
              - generic [ref=e209]:
                - generic [ref=e210]: Dec 16, 2025
                - generic [ref=e211]: "• Vendor update: Francis Peters (Illumina (vendor))"
          - generic [ref=e212]:
            - generic [ref=e214]: "#46"
            - generic [ref=e215]: +
            - generic [ref=e216]:
              - generic [ref=e217]:
                - generic [ref=e218]: CancerVista
                - generic [ref=e219]: MRD
                - generic [ref=e220]: LIQOMICS
              - paragraph [ref=e221]: "Added multi-solid tumor MRD assay from LIQOMICS. Technically validated with LoD 3.30×10⁻⁶. Covers 17 anatomical sites including bladder, brain, breast, cervix, colorectal, esophagus, head and neck, kidney, liver, lung, ovary, pancreas, prostate, skin, stomach, thyroid, and uterus. MRD detection: 80% sensitivity, 96.7% specificity, 94.3% accuracy at threshold 2.5×10⁻⁵. Variant detection: 93.17% sensitivity, >99% specificity for mAF ≥1%. 20 mL blood sample, 10-day TAT. Available in Europe."
              - generic [ref=e222]:
                - generic [ref=e223]: Dec 15, 2025
                - generic [ref=e224]: "• Vendor update: Jens Winter (LIQOMICS (vendor))"
          - generic [ref=e225]:
            - generic [ref=e227]: "#45"
            - generic [ref=e228]: +
            - generic [ref=e229]:
              - generic [ref=e230]:
                - generic [ref=e231]: IColocomf
                - generic [ref=e232]: ECD
                - generic [ref=e233]: Wuhan Ammunition Life Technology
              - paragraph [ref=e234]: Added NMPA/CE-approved stool DNA methylation test for CRC screening. Dual-target SDC2+TFPI2 qPCR assay. 95.31% CRC sensitivity, 96.93% Stage I-II sensitivity, 96.67% specificity vs healthy controls. Validated in independent multicenter trial (n=1,164) published in J Mol Diagn 2022. First Chinese stool DNA test in database. Available in China and Europe.
              - generic [ref=e235]:
                - generic [ref=e236]: Dec 15, 2025
                - generic [ref=e237]: "• Vendor update: Tingting Li (Wuhan Ammunition Life Technology (vendor))"
          - generic [ref=e238]:
            - generic [ref=e240]: "#44"
            - generic [ref=e241]: ↑
            - generic [ref=e242]:
              - generic [ref=e243]:
                - generic [ref=e244]: Data Accuracy Corrections
                - generic [ref=e245]: Multiple
              - paragraph [ref=e246]: "Corrected overstated claims and regulatory status: Cologuard - removed \"ONLY\" self-collection claim, moved USPSTF to guidelines field; TSO Comprehensive - narrowed CDx claims to FDA-labeled scope (NTRK/RET at launch); TSO 500 - clarified RUO in US; Oncomine Comprehensive Assay Plus - changed to RUO pending CE-IVD verification; GeneseeqPrime - corrected clearance date to Aug 2025; Epi proColon - updated reimbursement to \"coverage variable/limited\"; clonoSEQ - added US/EU distribution model notes."
              - generic [ref=e247]:
                - generic [ref=e248]: Dec 14, 2025
                - generic [ref=e249]: • OpenOnco
          - generic [ref=e250]:
            - generic [ref=e252]: "#43"
            - generic [ref=e253]: ↑
            - generic [ref=e254]:
              - generic [ref=e255]:
                - generic [ref=e256]: CDx Category Reclassification
                - generic [ref=e257]: Multiple
              - paragraph [ref=e258]: "Reclassified 6 therapy-selection companion diagnostics from TRM/MRD to TDS: cobas EGFR v2, cobas KRAS, therascreen EGFR, OncoBEAM RAS CRC, PGDx elio plasma focus (from TRM), and LeukoStrat CDx FLT3 (from MRD). These tests are primarily CDx for therapy selection, not treatment response monitoring or MRD detection. Category placement now reflects FDA-labeled intended use."
              - generic [ref=e259]:
                - generic [ref=e260]: Dec 14, 2025
                - generic [ref=e261]: • OpenOnco
          - generic [ref=e262]:
            - generic [ref=e264]: "#42"
            - generic [ref=e265]: ★
            - generic [ref=e266]:
              - generic [ref=e267]:
                - generic [ref=e268]: IVD Kit Support
                - generic [ref=e269]: All
              - paragraph [ref=e270]: "Added Product Type taxonomy distinguishing Self-Collection kits (patient collects at home), Laboratory IVD Kits (distributed reagents for CLIA labs), and Central Lab Services (send-out tests). New filter enables users to find tests by distribution model. Added 16 IVD kit entries: ECD - Cologuard, Epi proColon; MRD - clonoSEQ Assay, LymphoTrack Dx IGH Assay, BD OneFlow B-ALL MRD Kit; TDS - TruSight Oncology Comprehensive, GeneseeqPrime, PGDx elio tissue complete, Oncomine Comprehensive Assay Plus, TSO 500, cobas EGFR Mutation Test v2, cobas KRAS Mutation Test, therascreen EGFR RGQ PCR Kit, OncoBEAM RAS CRC Kit, PGDx elio plasma focus Dx, LeukoStrat CDx FLT3 Mutation Assay."
              - generic [ref=e271]:
                - generic [ref=e272]: Dec 14, 2025
                - generic [ref=e273]: • OpenOnco
          - generic [ref=e274]:
            - generic [ref=e276]: "#41"
            - generic [ref=e277]: +
            - generic [ref=e278]:
              - generic [ref=e279]:
                - generic [ref=e280]: Cologuard
                - generic [ref=e281]: ECD
                - generic [ref=e282]: Exact Sciences
              - paragraph [ref=e283]: Added FDA PMA-approved self-collection CRC screening kit. Only at-home collection cancer screening test. Stool DNA + FIT, 92% CRC sensitivity, 87% specificity. USPSTF Grade A recommendation.
              - generic [ref=e284]:
                - generic [ref=e285]: Dec 14, 2025
                - generic [ref=e286]: • OpenOnco
          - generic [ref=e287]:
            - generic [ref=e289]: "#40"
            - generic [ref=e290]: +
            - generic [ref=e291]:
              - generic [ref=e292]:
                - generic [ref=e293]: clonoSEQ Assay
                - generic [ref=e294]: MRD
                - generic [ref=e295]: Adaptive Biotechnologies
              - paragraph [ref=e296]: Added FDA-cleared IVD kit for MRD detection in hematologic malignancies. First and only FDA-cleared MRD IVD. Available as reagent kit for MiSeqDx labs.
              - generic [ref=e297]:
                - generic [ref=e298]: Dec 14, 2025
                - generic [ref=e299]: • OpenOnco
          - generic [ref=e300]:
            - generic [ref=e302]: "#39"
            - generic [ref=e303]: +
            - generic [ref=e304]:
              - generic [ref=e305]:
                - generic [ref=e306]: TruSight Oncology Comprehensive
                - generic [ref=e307]: TDS
                - generic [ref=e308]: Illumina
              - paragraph [ref=e309]: Added first FDA-approved distributable CGP IVD kit with pan-cancer CDx claims. 517 genes, enables in-house comprehensive genomic profiling.
              - generic [ref=e310]:
                - generic [ref=e311]: Dec 14, 2025
                - generic [ref=e312]: • OpenOnco
          - generic [ref=e313]:
            - generic [ref=e315]: "#38"
            - generic [ref=e316]: +
            - generic [ref=e317]:
              - generic [ref=e318]:
                - generic [ref=e319]: cobas EGFR Mutation Test v2
                - generic [ref=e320]: TDS
                - generic [ref=e321]: Roche
              - paragraph [ref=e322]: Added FDA-approved EGFR liquid biopsy CDx kit. First liquid biopsy test FDA-approved (2016). Gold standard for EGFR TKI therapy selection.
              - generic [ref=e323]:
                - generic [ref=e324]: Dec 14, 2025
                - generic [ref=e325]: • OpenOnco
          - generic [ref=e326]:
            - generic [ref=e328]: "#37"
            - generic [ref=e329]: ↑
            - generic [ref=e330]:
              - generic [ref=e331]:
                - generic [ref=e332]: Reveal TRM
                - generic [ref=e333]: TRM
                - generic [ref=e334]: Guardant Health
              - paragraph [ref=e335]: "Corrected tumor fraction methodology for Reveal TRM and Reveal MRD: epiTF (epigenetic Tumor Fraction) calculated from 19,000+ differentially methylated loci, mutation-agnostic. Removed duplicate Guardant360 Response entry (trm-10)."
              - generic [ref=e336]:
                - generic [ref=e337]: Dec 13, 2025
                - generic [ref=e338]: "• Vendor update: Brandon Guida (Guardant Health (vendor))"
          - generic [ref=e339]:
            - generic [ref=e341]: "#36"
            - generic [ref=e342]: +
            - generic [ref=e343]:
              - generic [ref=e344]:
                - generic [ref=e345]: IsoPSA
                - generic [ref=e346]: TDS
                - generic [ref=e347]: Cleveland Diagnostics
              - paragraph [ref=e348]: Added FDA PMA-approved protein structure-based prostate cancer diagnostic. IsoClear platform analyzes PSA structural variants (not concentration) to aid biopsy decisions. 90.2% sensitivity, runs on standard analyzers (COBAS, Siemens, Abbott). In NCCN and AUA/SUO guidelines, Medicare covered.
              - generic [ref=e349]:
                - generic [ref=e350]: Dec 13, 2025
                - generic [ref=e351]: "• Vendor update: Sameer Rohatgi (Cleveland Diagnostics)"
          - generic [ref=e352]:
            - generic [ref=e354]: "#35"
            - generic [ref=e355]: ↑
            - generic [ref=e356]:
              - generic [ref=e357]:
                - generic [ref=e358]: LymphoVista
                - generic [ref=e359]: MRD
                - generic [ref=e360]: LIQOMICS
              - paragraph [ref=e361]: "Corrected turnaround times per vendor: Initial TAT and Follow-up TAT both 10 days (previously listed as 2-4 weeks)."
              - generic [ref=e362]:
                - generic [ref=e363]: Dec 13, 2025
                - generic [ref=e364]: "• Vendor update: Jens Winter (LIQOMICS (vendor))"
          - generic [ref=e365]:
            - generic [ref=e367]: "#34"
            - generic [ref=e368]: ↑
            - generic [ref=e369]:
              - generic [ref=e370]:
                - generic [ref=e371]: Northstar Select
                - generic [ref=e372]: TDS
                - generic [ref=e373]: BillionToOne
              - paragraph [ref=e374]: "Updated reimbursement status: Medicare coverage via MolDx (Palmetto GBA LCD L38043) effective February 14, 2025."
              - generic [ref=e375]:
                - generic [ref=e376]: Dec 12, 2025
                - generic [ref=e377]: "• Vendor update: David Huland (BillionToOne (vendor))"
          - generic [ref=e378]:
            - generic [ref=e380]: "#33"
            - generic [ref=e381]: ↑
            - generic [ref=e382]:
              - generic [ref=e383]:
                - generic [ref=e384]: Guardant360 Response (DISCONTINUED)
                - generic [ref=e385]: TRM
                - generic [ref=e386]: Guardant Health
              - paragraph [ref=e387]: "PRODUCT DISCONTINUED: Sun-setted per vendor. Guardant has consolidated monitoring portfolio to Reveal MRD (early-stage) and Reveal TRM (advanced/metastatic). Guardant360 Response is no longer commercially available."
              - generic [ref=e388]:
                - generic [ref=e389]: Dec 12, 2025
                - generic [ref=e390]: "• Vendor update: Brandon Guida PhD (Guardant Health (vendor))"
          - generic [ref=e391]:
            - generic [ref=e393]: "#32"
            - generic [ref=e394]: +
            - generic [ref=e395]:
              - generic [ref=e396]:
                - generic [ref=e397]: Reveal TRM
                - generic [ref=e398]: TRM
                - generic [ref=e399]: Guardant Health
              - paragraph [ref=e400]: Added new methylation-based therapy response monitoring test for advanced/metastatic solid tumors. Uses Guardant Infinity platform with epigenetic tumor fraction (epiTF) quantification from 19,000+ differentially methylated loci—mutation-agnostic. Precision down to ~0.01% TF, not confounded by CNAs or CHIP. Validated in >50,000 cfDNA samples across 20+ cancer types (AACR 2025).
              - generic [ref=e401]:
                - generic [ref=e402]: Dec 12, 2025
                - generic [ref=e403]: "• Vendor update: Brandon Guida PhD (Guardant Health (vendor))"
          - generic [ref=e404]:
            - generic [ref=e406]: "#31"
            - generic [ref=e407]: ↑
            - generic [ref=e408]:
              - generic [ref=e409]:
                - generic [ref=e410]: Reveal MRD
                - generic [ref=e411]: MRD
                - generic [ref=e412]: Guardant Health
              - paragraph [ref=e413]: Renamed from "Reveal" to "Reveal MRD" per vendor product consolidation. Expanded cancer types to include breast and non-small cell lung cancer (previously CRC only). Early-stage cancer focus for MRD detection/recurrence monitoring after curative-intent therapy.
              - generic [ref=e414]:
                - generic [ref=e415]: Dec 12, 2025
                - generic [ref=e416]: "• Vendor update: Brandon Guida PhD (Guardant Health (vendor))"
          - generic [ref=e417]:
            - generic [ref=e419]: "#30"
            - generic [ref=e420]: ★
            - generic [ref=e421]:
              - generic [ref=e423]: Site Update
              - paragraph [ref=e424]: Added shareable comparison links (copy link button in comparison modal). Fixed print-to-PDF bug that repeated Page 1 on all pages.
              - generic [ref=e425]:
                - generic [ref=e426]: Dec 13, 2025
                - generic [ref=e427]: • Jeff Hull (BillionToOne (via LinkedIn))
          - generic [ref=e428]:
            - generic [ref=e430]: "#29"
            - generic [ref=e431]: ↑
            - generic [ref=e432]:
              - generic [ref=e433]:
                - generic [ref=e434]: Foresight CLARITY Lymphoma
                - generic [ref=e435]: MRD
                - generic [ref=e436]: Natera
              - paragraph [ref=e437]: "Updated per vendor: Matched Normal = Yes; LOD95 = 0.7 ppm (previously listed as LOD). Added analytical validation publication citation."
              - generic [ref=e438]:
                - generic [ref=e439]: Dec 13, 2025
                - generic [ref=e440]: "• Vendor update: John Truesdell (Natera/Foresight (vendor))"
          - generic [ref=e441]:
            - generic [ref=e443]: "#28"
            - generic [ref=e444]: ↑
            - generic [ref=e445]:
              - generic [ref=e446]:
                - generic [ref=e447]: NeXT Personal Dx
                - generic [ref=e448]: MRD
                - generic [ref=e449]: Personalis
              - paragraph [ref=e450]: "Updated turnaround times per vendor: initial TAT now 21 days (was 35), follow-up TAT now 10 days (was 12). Confirmed blood volume (20 mL, two Streck tubes) and variants tracked (~1,800)."
              - generic [ref=e451]:
                - generic [ref=e452]: Dec 12, 2025
                - generic [ref=e453]: "• Vendor update: Dan Norton (Personalis (vendor))"
          - generic [ref=e454]:
            - generic [ref=e456]: "#27"
            - generic [ref=e457]: ↑
            - generic [ref=e458]:
              - generic [ref=e459]:
                - generic [ref=e460]: clonoSEQ
                - generic [ref=e461]: MRD
                - generic [ref=e462]: Adaptive Biotechnologies
              - paragraph [ref=e463]: "Clarified sample requirements: baseline Clonality (ID) test accepts fresh or archived samples from bone marrow aspirate, peripheral blood, or soft tissue (e.g., plasmacytoma, lymph node biopsy). Subsequent Tracking (MRD) tests use standard fresh bone marrow or blood."
              - generic [ref=e464]:
                - generic [ref=e465]: Dec 11, 2025
                - generic [ref=e466]: "• Vendor update: Christine Hanley (Adaptive Biotechnologies (vendor))"
          - generic [ref=e467]:
            - generic [ref=e469]: "#26"
            - generic [ref=e470]: +
            - generic [ref=e471]:
              - generic [ref=e472]:
                - generic [ref=e473]: Guardant360 Liquid
                - generic [ref=e474]: TDS
                - generic [ref=e475]: Guardant Health
              - paragraph [ref=e476]: "Added comprehensive 744-gene liquid biopsy LDT (distinct from 74-gene FDA-approved CDx). Features: genomic + epigenomic (promoter methylation) insights, CHIP filtering, virus detection (EBV/HPV), tumor fraction quantification. Runs on Guardant Infinity platform with 10x more genes and 10x higher sensitivity than previous version."
              - generic [ref=e477]:
                - generic [ref=e478]: Dec 11, 2025
                - generic [ref=e479]: "• Vendor update: Brandon (Scott) Guida PhD (Guardant Health (vendor))"
          - generic [ref=e480]:
            - generic [ref=e482]: "#25"
            - generic [ref=e483]: ★
            - generic [ref=e484]:
              - generic [ref=e485]:
                - generic [ref=e486]: Clinical Settings Tags
                - generic [ref=e487]: MRD
              - paragraph [ref=e488]: "Added clinicalSettings field to all MRD tests to capture validated clinical contexts: Neoadjuvant (monitoring during pre-surgery therapy), Post-Surgery (landmark ~4 weeks after resection), Post-Adjuvant (after chemotherapy), and Surveillance (longitudinal recurrence monitoring). Added filter by clinical setting. Based on vendor feedback from Personalis (Dan Norton) on clinical context-specific performance data."
              - generic [ref=e489]:
                - generic [ref=e490]: Dec 11, 2025
                - generic [ref=e491]: • Dan Norton (Personalis)
          - generic [ref=e492]:
            - generic [ref=e494]: "#24"
            - generic [ref=e495]: +
            - generic [ref=e496]:
              - generic [ref=e497]:
                - generic [ref=e498]: LymphoVista
                - generic [ref=e499]: MRD
                - generic [ref=e500]: LIQOMICS
              - paragraph [ref=e501]: "Added European lymphoma-focused ctDNA MRD test covering B-cell lymphomas (DLBCL, FL, MCL, Burkitt, CNS) and Hodgkin lymphoma via LymphoVista HL variant. Duplex sequencing with LoD 6.69×10⁻⁶. Clinical validation: 92.1% PPV in r/r DLBCL post-CAR-T/chemo (EHA 2024); HR 6.9 for PFS in Hodgkin (ASH 2024, HD21 trial)."
              - generic [ref=e502]:
                - generic [ref=e503]: Dec 12, 2025
                - generic [ref=e504]: "• Vendor update: Jens Winter (LIQOMICS (vendor))"
          - generic [ref=e505]:
            - generic [ref=e507]: "#23"
            - generic [ref=e508]: +
            - generic [ref=e509]:
              - generic [ref=e510]:
                - generic [ref=e511]: CancerDetect
                - generic [ref=e512]: MRD
                - generic [ref=e513]: IMBdx
              - paragraph [ref=e514]: Added Korean tumor-informed MRD test using large-scale mutation tracking (up to 300 variants). 0.001% LOD. Innovative Medical Technology designation.
              - generic [ref=e515]:
                - generic [ref=e516]: Dec 11, 2025
                - generic [ref=e517]: "• Vendor update: Sunghoon Heo (IMBdx (vendor))"
          - generic [ref=e518]:
            - generic [ref=e520]: "#22"
            - generic [ref=e521]: +
            - generic [ref=e522]:
              - generic [ref=e523]:
                - generic [ref=e524]: Latitude
                - generic [ref=e525]: MRD
                - generic [ref=e526]: Natera
              - paragraph [ref=e527]: Added tissue-free (tumor-naïve) methylation-based MRD test for CRC. No tumor tissue required. Validated in CIRCULATE-JAPAN GALAXY Study.
              - generic [ref=e528]:
                - generic [ref=e529]: Dec 11, 2025
                - generic [ref=e530]: • Sunghoon Heo (IMBdx)
          - generic [ref=e531]:
            - generic [ref=e533]: "#21"
            - generic [ref=e534]: +
            - generic [ref=e535]:
              - generic [ref=e536]:
                - generic [ref=e537]: Signatera Genome
                - generic [ref=e538]: MRD
                - generic [ref=e539]: Natera
              - paragraph [ref=e540]: Added WGS-informed version of Signatera with 64 variants tracked and 1 ppm LOD (~100x more sensitive than standard Signatera).
              - generic [ref=e541]:
                - generic [ref=e542]: Dec 11, 2025
                - generic [ref=e543]: • Sunghoon Heo (IMBdx)
          - generic [ref=e544]:
            - generic [ref=e546]: "#20"
            - generic [ref=e547]: ↑
            - generic [ref=e548]:
              - generic [ref=e549]:
                - generic [ref=e550]: Labcorp Plasma Detect
                - generic [ref=e551]: MRD
                - generic [ref=e552]: Labcorp
              - paragraph [ref=e553]: "Fixed duplicate entry: merged mrd-17 into mrd-9. Updated with expanded cancer types (lung, bladder in validation), improved LOD (10 ppm), lead time data, and newer clinical trial citations."
              - generic [ref=e554]:
                - generic [ref=e555]: Dec 11, 2025
                - generic [ref=e556]: • Sunghoon Heo (IMBdx)
          - generic [ref=e557]:
            - generic [ref=e559]: "#19"
            - generic [ref=e560]: ↑
            - generic [ref=e561]:
              - generic [ref=e562]:
                - generic [ref=e563]: NEO PanTracer Tissue
                - generic [ref=e564]: TDS
                - generic [ref=e565]: NeoGenomics
              - paragraph [ref=e566]: Renamed from "Neo Comprehensive" to "NEO PanTracer Tissue" to reflect NeoGenomics product rebrand.
              - generic [ref=e567]:
                - generic [ref=e568]: Dec 10, 2025
                - generic [ref=e569]: • Heather Robinson (Illumina)
          - generic [ref=e570]:
            - generic [ref=e572]: "#18"
            - generic [ref=e573]: ↑
            - generic [ref=e574]:
              - generic [ref=e575]:
                - generic [ref=e576]: clonoSEQ
                - generic [ref=e577]: MRD
                - generic [ref=e578]: Adaptive Biotechnologies
              - paragraph [ref=e579]: "Vendor update: TAT changed to 7 days (serial monitoring) from 14 days (baseline); updated Target Population to list specific indications (ALL, CLL, DLBCL, MCL, MM); clarified tumor tissue requirement for hematologic assay."
              - generic [ref=e580]:
                - generic [ref=e581]: Dec 10, 2025
                - generic [ref=e582]: "• Vendor update: Christine Hanley (Adaptive Biotechnologies)"
          - generic [ref=e583]:
            - generic [ref=e585]: "#17"
            - generic [ref=e586]: ★
            - generic [ref=e587]:
              - generic [ref=e588]:
                - generic [ref=e589]: Medicare ADLT Data
                - generic [ref=e590]: All
              - paragraph [ref=e591]: "Added Medicare CLFS reimbursement rates and ADLT status to 8 tests: Signatera ($3,500), Guardant360 CDx ($5,000), FoundationOne CDx ($3,500), FoundationOne Liquid CDx ($3,500), Shield ($1,495), NavDx ($1,800), Tempus xT CDx ($4,500), clonoSEQ ($2,007). Added PLA vs CPT code type distinction."
              - generic [ref=e592]:
                - generic [ref=e593]: Dec 10, 2025
                - generic [ref=e594]: • OpenOnco
          - generic [ref=e595]:
            - generic [ref=e597]: "#16"
            - generic [ref=e598]: +
            - generic [ref=e599]:
              - generic [ref=e600]:
                - generic [ref=e601]: clonoSEQ
                - generic [ref=e602]: MRD
                - generic [ref=e603]: Adaptive Biotechnologies
              - paragraph [ref=e604]: Added clonoSEQ - first and only FDA-cleared MRD test for hematologic malignancies (MM, B-ALL, CLL). Uses NGS immunosequencing of B/T-cell receptor genes with 10⁻⁶ sensitivity. Medicare coverage for MM, ALL, CLL, DLBCL, MCL.
              - generic [ref=e605]:
                - generic [ref=e606]: Dec 10, 2025
                - generic [ref=e607]: "• Vendor update: Christine Hanley (Adaptive Biotechnologies)"
          - generic [ref=e608]:
            - generic [ref=e610]: "#15"
            - generic [ref=e611]: ↑
            - generic [ref=e612]:
              - generic [ref=e613]:
                - generic [ref=e614]: FoundationOne CDx
                - generic [ref=e615]: TDS
                - generic [ref=e616]: Foundation Medicine
              - paragraph [ref=e617]: Added international availability info - available in 100+ countries via Roche global network (EU lab in Penzberg, Germany; MHLW approved in Japan)
              - generic [ref=e618]:
                - generic [ref=e619]: Dec 10, 2025
                - generic [ref=e620]: • OpenOnco
          - generic [ref=e621]:
            - generic [ref=e623]: "#14"
            - generic [ref=e624]: ↑
            - generic [ref=e625]:
              - generic [ref=e626]:
                - generic [ref=e627]: FoundationOne Liquid CDx
                - generic [ref=e628]: TDS
                - generic [ref=e629]: Foundation Medicine
              - paragraph [ref=e630]: Added international availability info - available in 100+ countries via Roche global network
              - generic [ref=e631]:
                - generic [ref=e632]: Dec 10, 2025
                - generic [ref=e633]: • OpenOnco
          - generic [ref=e634]:
            - generic [ref=e636]: "#13"
            - generic [ref=e637]: ↑
            - generic [ref=e638]:
              - generic [ref=e639]:
                - generic [ref=e640]: FoundationOne Heme
                - generic [ref=e641]: TDS
                - generic [ref=e642]: Foundation Medicine
              - paragraph [ref=e643]: Added international availability info - available via Roche global network
              - generic [ref=e644]:
                - generic [ref=e645]: Dec 10, 2025
                - generic [ref=e646]: • OpenOnco
          - generic [ref=e647]:
            - generic [ref=e649]: "#12"
            - generic [ref=e650]: ↑
            - generic [ref=e651]:
              - generic [ref=e652]:
                - generic [ref=e653]: FoundationOne Tracker (MRD)
                - generic [ref=e654]: MRD
                - generic [ref=e655]: Foundation Medicine
              - paragraph [ref=e656]: Added international availability info for investigational/early access program
              - generic [ref=e657]:
                - generic [ref=e658]: Dec 10, 2025
                - generic [ref=e659]: • OpenOnco
          - generic [ref=e660]:
            - generic [ref=e662]: "#11"
            - generic [ref=e663]: ↑
            - generic [ref=e664]:
              - generic [ref=e665]:
                - generic [ref=e666]: Foundation TI-WGS MRD (RUO)
                - generic [ref=e667]: MRD
                - generic [ref=e668]: Foundation Medicine
              - paragraph [ref=e669]: Added international availability info for RUO via FlexOMx Lab
              - generic [ref=e670]:
                - generic [ref=e671]: Dec 10, 2025
                - generic [ref=e672]: • OpenOnco
          - generic [ref=e673]:
            - generic [ref=e675]: "#10"
            - generic [ref=e676]: ↑
            - generic [ref=e677]:
              - generic [ref=e678]:
                - generic [ref=e679]: FoundationOne Tracker (TRM)
                - generic [ref=e680]: TRM
                - generic [ref=e681]: Foundation Medicine
              - paragraph [ref=e682]: Added international availability info - available via Roche affiliates
              - generic [ref=e683]:
                - generic [ref=e684]: Dec 10, 2025
                - generic [ref=e685]: • OpenOnco
          - generic [ref=e686]:
            - generic [ref=e688]: "#9"
            - generic [ref=e689]: ↑
            - generic [ref=e690]:
              - generic [ref=e691]:
                - generic [ref=e692]: FoundationOne Monitor
                - generic [ref=e693]: TRM
                - generic [ref=e694]: Foundation Medicine
              - paragraph [ref=e695]: Added international availability info - available via Roche affiliates
              - generic [ref=e696]:
                - generic [ref=e697]: Dec 10, 2025
                - generic [ref=e698]: • OpenOnco
          - generic [ref=e699]:
            - generic [ref=e701]: "#8"
            - generic [ref=e702]: +
            - generic [ref=e703]:
              - generic [ref=e704]:
                - generic [ref=e705]: Northstar Select
                - generic [ref=e706]: TDS
                - generic [ref=e707]: BillionToOne
              - paragraph [ref=e708]: Initial database entry - liquid biopsy CGP with 0.15% VAF LOD
              - generic [ref=e709]:
                - generic [ref=e710]: Dec 9, 2025
                - generic [ref=e711]: "• Vendor update: Rob Manor (BillionToOne)"
          - generic [ref=e712]:
            - generic [ref=e714]: "#7"
            - generic [ref=e715]: ↑
            - generic [ref=e716]:
              - generic [ref=e717]:
                - generic [ref=e718]: Northstar Response
                - generic [ref=e719]: TRM
                - generic [ref=e720]: BillionToOne
              - paragraph [ref=e721]: Updated methylated loci count from >500 to >2200 (v2 panel expansion)
              - generic [ref=e722]:
                - generic [ref=e723]: Dec 9, 2025
                - generic [ref=e724]: "• Vendor update: Rob Manor (BillionToOne)"
          - generic [ref=e725]:
            - generic [ref=e727]: "#6"
            - generic [ref=e728]: −
            - generic [ref=e729]:
              - generic [ref=e730]:
                - generic [ref=e731]: MSK-ACCESS powered with SOPHiA DDM
                - generic [ref=e732]: TRM
                - generic [ref=e733]: SOPHiA GENETICS
              - paragraph [ref=e734]: Removed - RUO kitted product not directly orderable by physicians. Vendor confirmed test does not meet inclusion criteria.
              - generic [ref=e735]:
                - generic [ref=e736]: Dec 10, 2025
                - generic [ref=e737]: "• Vendor update: Julien Pontis (SOPHiA GENETICS)"
          - generic [ref=e738]:
            - generic [ref=e740]: "#5"
            - generic [ref=e741]: +
            - generic [ref=e742]:
              - generic [ref=e743]:
                - generic [ref=e744]: Invitae PCM
                - generic [ref=e745]: MRD
                - generic [ref=e746]: Labcorp (Invitae)
              - paragraph [ref=e747]: Initial database entry
              - generic [ref=e748]:
                - generic [ref=e749]: Dec 8, 2025
                - generic [ref=e750]: • OpenOnco
          - generic [ref=e751]:
            - generic [ref=e753]: "#4"
            - generic [ref=e754]: +
            - generic [ref=e755]:
              - generic [ref=e756]:
                - generic [ref=e757]: Neo Comprehensive
                - generic [ref=e758]: TDS
                - generic [ref=e759]: NeoGenomics
              - paragraph [ref=e760]: Initial database entry
              - generic [ref=e761]:
                - generic [ref=e762]: Dec 8, 2025
                - generic [ref=e763]: • OpenOnco
          - generic [ref=e764]:
            - generic [ref=e766]: "#3"
            - generic [ref=e767]: +
            - generic [ref=e768]:
              - generic [ref=e769]:
                - generic [ref=e770]: Signal-C
                - generic [ref=e771]: ECD
                - generic [ref=e772]: Universal DX
              - paragraph [ref=e773]: Initial database entry
              - generic [ref=e774]:
                - generic [ref=e775]: Dec 7, 2025
                - generic [ref=e776]: • OpenOnco
          - generic [ref=e777]:
            - generic [ref=e779]: "#2"
            - generic [ref=e780]: +
            - generic [ref=e781]:
              - generic [ref=e782]:
                - generic [ref=e783]: Foresight CLARITY Lymphoma
                - generic [ref=e784]: MRD
                - generic [ref=e785]: Natera
              - paragraph [ref=e786]: Initial database entry
              - generic [ref=e787]:
                - generic [ref=e788]: Dec 7, 2025
                - generic [ref=e789]: • John Truesdell (Foresight Diagnostics)
          - generic [ref=e790]:
            - generic [ref=e792]: "#1"
            - generic [ref=e793]: +
            - generic [ref=e794]:
              - generic [ref=e795]:
                - generic [ref=e796]: EPISEEK
                - generic [ref=e797]: ECD
                - generic [ref=e798]: Precision Epigenomics
              - paragraph [ref=e799]: Initial database entry
              - generic [ref=e800]:
                - generic [ref=e801]: Dec 5, 2025
                - generic [ref=e802]: "• Vendor update: Richard Bernert (Precision Epigenomics)"
  - contentinfo [ref=e803]:
    - generic [ref=e804]:
      - paragraph [ref=e805]:
        - strong [ref=e806]: "Disclaimer:"
        - text: OpenOnco is provided for informational and educational purposes only. The information on this website is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. OpenOnco does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Nothing on this website constitutes reimbursement or coverage guidance, and should not be used to determine insurance coverage, patient financial responsibility, or billing practices. Reliance on any information provided by OpenOnco is solely at your own risk. Test performance data, pricing, and availability are subject to change and should be verified directly with test vendors.
      - paragraph [ref=e807]: "Built: Dec 21, 2025, 09:01 AM PST"
```